Home>News> Gilead turbocharges production of COVID-19 hopeful remdesivir

Gilead turbocharges production of COVID-19 hopeful remdesivir

Gilead Sciences’ remdesivir has courted high hopes as a potential treatment for COVID-19—so high, in fact, that the company previously had to shut down emergency access to the drug. Now, Gilead’s revving up manufacturing of remdesivir to operate at light speed.
 
Gilead has stepped on the gas pedal to ramp up production of the coronavirus candidate, CEO Daniel O’Day said in an open letter Saturday, including making “process improvements” that have cut remdesivir’s manufacturing timeline in half from one year to six months.

Tags: